| P50 | author | Geert D'Haens | Q37066728 |
| P2093 | author name string | Vipul Jairath | |
| | Pieter Hindryckx | |
| P2860 | cites work | PTU-061 Infliximab Or Ciclosporin: Patients’ Treatment Preferences And The Impact Of Ulcerative Colitis (uc) On Their Lives | Q57460500 |
| | Continuous Infusion Versus Bolus Administration of Steroids in Severe Attacks of Ulcerative Colitis: A Randomized, Double-Blind Trial | Q60023304 |
| | Ulcerative colitis: Female fecundity before diagnosis, during disease, and after surgery compared with a population sample | Q61897071 |
| | Acetic acid-induced colitis in the rat: a reproducible experimental model for acute ulcerative colitis | Q68019052 |
| | An index of disease activity in patients with ulcerative colitis | Q68231324 |
| | Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis | Q70539279 |
| | Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity | Q72048490 |
| | Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis | Q72688420 |
| | Neutralization of tumour necrosis factor (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice | Q73068273 |
| | Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy | Q74063708 |
| | Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid | Q74363256 |
| | Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study | Q74601127 |
| | Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis | Q79631486 |
| | Management of acute severe colitis | Q79922499 |
| | Impact of Clostridium difficile on inflammatory bowel disease | Q79971516 |
| | Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients | Q83083855 |
| | Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response | Q83086029 |
| | Successive treatment with cyclosporine and infliximab in steroid-refractory ulcerative colitis | Q83567286 |
| | Early predictors of responses and clinical outcomes of corticosteroid treatment for severe ulcerative colitis | Q87304477 |
| | Guidelines for the management of inflammatory bowel disease in adults | Q22242049 |
| | Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review | Q22250934 |
| | Traditional corticosteroids for induction of remission in Crohn's disease | Q24242955 |
| | Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice | Q24523182 |
| | Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitis | Q26823221 |
| | Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update | Q26994776 |
| | Review article: defining remission in ulcerative colitis | Q28238641 |
| | Antiinflammatory action of glucocorticoids--new mechanisms for old drugs | Q28278037 |
| | Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) | Q28284893 |
| | Infliximab for induction and maintenance therapy for ulcerative colitis | Q28285876 |
| | Genetic predictors of medically refractory ulcerative colitis | Q28943368 |
| | Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. | Q33268368 |
| | An antibiotic-responsive mouse model of fulminant ulcerative colitis | Q33322360 |
| | Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee | Q33523446 |
| | Mechanisms of action of cyclosporine. | Q33908049 |
| | Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) | Q34047972 |
| | Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 |
| | Alterations in the gut microbiome of children with severe ulcerative colitis | Q34101549 |
| | Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases | Q34173855 |
| | Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis | Q34213109 |
| | Small bowel gas in severe ulcerative colitis | Q34395164 |
| | Predicting outcome in severe ulcerative colitis | Q34409849 |
| | THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS. | Q34478028 |
| | Review article: acute severe ulcerative colitis - evidence-based consensus statements. | Q34528270 |
| | Controlled trial of bowel rest in the treatment of severe acute colitis | Q34529542 |
| | Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis | Q34538009 |
| | Cytomegalovirus colitis complicating inflammatory bowel disease | Q34572006 |
| | Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? | Q35596373 |
| | Influence of intestinal bacteria on induction of regulatory T cells: lessons from a transfer model of colitis | Q35597887 |
| | Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial | Q35598580 |
| | Less adhesiolysis and hernia repair during completion proctocolectomy after laparoscopic emergency colectomy for ulcerative colitis | Q35681128 |
| | Predictors of aggressive inflammatory bowel disease | Q35691407 |
| | Immunopathogenesis of IBD: current state of the art. | Q35857951 |
| | Review article: the practical management of acute severe ulcerative colitis | Q35883580 |
| | Pharmacological Evaluation of the SCID T Cell Transfer Model of Colitis: As a Model of Crohn's Disease | Q35895310 |
| | Mortality in patients with and without colectomy admitted to hospital for ulcerative colitis and Crohn's disease: record linkage studies | Q36145711 |
| | Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression | Q36671830 |
| | Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations | Q36939821 |
| | Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults | Q37035957 |
| | Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease | Q37051414 |
| | Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial | Q37196938 |
| | Animal models of ulcerative colitis and their application in drug research | Q37312835 |
| | Colonoscopic perforation in inflammatory bowel disease | Q37698479 |
| | The pattern and outcome of acute severe colitis | Q37814560 |
| | Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. | Q37853361 |
| | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management | Q38049776 |
| | Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations | Q38049779 |
| | Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease | Q38066200 |
| | Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. | Q38194708 |
| | European evidence based consensus on surgery for ulcerative colitis | Q38258954 |
| | Review article: cytomegalovirus and inflammatory bowel disease | Q38356619 |
| | Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks? | Q38404037 |
| | Biomarkers of Inflammation in Inflammatory Bowel Disease | Q38545702 |
| | Genetics of Inflammatory Bowel Diseases | Q38563101 |
| | Therapeutic innovations in inflammatory bowel diseases | Q38618178 |
| | Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids | Q38726448 |
| | Management of Acute Severe Colitis in Children With Ulcerative Colitis in the Biologics Era. | Q38849086 |
| | Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial | Q38904169 |
| | Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis. | Q39829049 |
| | Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients | Q40051749 |
| | Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment | Q40528913 |
| | Toxic megacolon and human Cytomegalovirus in a series of severe ulcerative colitis patients | Q41340614 |
| | The role of bacteria in the pathogenesis of ulcerative colitis | Q41860050 |
| | Assessment of severity in colitis: a preliminary study | Q41988487 |
| | Electrolyte and acid-base disorders in inflammatory bowel disease | Q42406557 |
| | Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications | Q43184169 |
| | Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis | Q43560942 |
| | Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis | Q43798421 |
| | Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study | Q44319021 |
| | Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis | Q44380215 |
| | A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice | Q44753508 |
| | Intestinal superinfections in patients with inflammatory bowel diseases | Q44774030 |
| | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients | Q45004028 |
| | Phylogenetic analysis of dysbiosis in ulcerative colitis during remission | Q45367129 |
| | Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. | Q45926125 |
| | Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. | Q46531976 |
| | Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease | Q46732211 |
| | Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. | Q50943829 |
| | A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. | Q50968026 |
| | An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. | Q51064950 |
| | Derivation of a T2-weighted MRI total colonic inflammation score (TCIS) for assessment of patients with severe acute inflammatory colitis-a preliminary study. | Q51665884 |
| | Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 |
| | Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. | Q53463453 |
| | Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. | Q53579269 |
| | Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis. | Q53657609 |
| | A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. | Q53964227 |
| | Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. | Q54007642 |
| | Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. | Q54115144 |
| | Intensive intravenous regimen for severe attacks of ulcerative colitis. | Q54394687 |
| | Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. | Q54563945 |
| | Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. | Q54568296 |
| | Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. | Q55228737 |
| | Cortisone in ulcerative colitis; final report on a therapeutic trial. | Q55499879 |
| | Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial man | Q57265461 |
| | ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach | Q57309663 |
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| | pathophysiology | Q1135939 |
| P304 | page(s) | 654-664 | |
| P577 | publication date | 2016-09-01 | |
| P1433 | published in | Nature Reviews Gastroenterology & Hepatology | Q2108255 |
| P1476 | title | Acute severe ulcerative colitis: from pathophysiology to clinical management | |
| P478 | volume | 13 | |